title: Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia.
authors.affiliation: Lehigh Valley Health Network, Allentown, PA ranjit_r.nair@lvhn.org.
authors.forename: Ranjit
authors.initials: R
authors.lastname: Nair
authors.affiliation: Lehigh Valley Health Network, Allentown, PA ranjit_r.nair@lvhn.org.
authors.forename: Shereen
authors.initials: S
authors.lastname: Gheith
authors.affiliation: Lehigh Valley Health Network, Allentown, PA ranjit_r.nair@lvhn.org.
authors.forename: Suresh G
authors.initials: SG
authors.lastname: Nair
mesh_terms: D000743:Anemia, Hemolytic / Q000209:etiology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008875:Middle Aged; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen; D005938:Glucocorticoids; D000074324:Ipilimumab; C582435:pembrolizumab